Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Inovio Pharmaceuticals Inc (INO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.45-10.49%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for INO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS loss narrows from -$1.14 in 2026 to -$0.41 in 2027 | A supporting condition in Inovio Pharmaceuticals Inc's published investment case. The stated target is EPS improves from -$1.14 in 2026 to -$0.41 in 2027. | Improving | EPS loss worsens or remains below -$1.0 in 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making development-stage biotech with a potential product launch as its main source of business upside. The long-term thesis is in a watch state: management has made progress toward its regulatory timeline, but recent financial performance remains below its industry cohort.
The valuation is at a premium to peers, with optionality, or value tied to possible future outcomes, driving the difference. Model confidence is low, and the valuation measure rose recently, so expectations may already give weight to progress toward an INO-3107 launch; the evidence does not show how much launch success the market assumes.
Near term, management is progressing INO-3107 toward its stated FDA review milestone and has begun launch preparations, while operational cash burn remains around its stated range. Recent earnings announcements were positive, but performance still trails the industry cohort, and the company has raised capital to support operations into early 2027. The next report carries elevated risk, including the possibility of weaker guidance.
Over the next several quarters, the key swing factor is whether INO-3107 advances through FDA review and toward commercial launch on management’s timeline. The multi-year view also depends on cash-burn control and access to funding, while weaker employment data or guidance cuts could add pressure. Continued strength from healthcare peers could support the sector backdrop, though it would not resolve company-specific execution risks.
For the 1-to-3-year view, INO remains a high-risk, loss-making story centered on regulatory progress and funding discipline, with limited confidence in the valuation evidence. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Inovio aims to reduce operational net cash burn to about $18 million in 2026-Q2. |
| Improving |
| operational net cash burn exceeds $18 million in 2026-Q2 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth from $2.3 million in 2026-Q3 to $69 million in 2027 | A primary condition in Inovio Pharmaceuticals Inc's published investment case. The stated target is grow from $2.3 million in 2026-Q3 to $69 million in 2027. | Improving | revenue fails to grow above $10 million in 2026 or $50 million in 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.50 → $-0.41 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.50 | $51,305,333 | 3 / 3 |
| 2026-07-25 | $-0.50 | $51,305,333 | 3 / 3 |
| 2026-07-26 | $-0.50 | $51,305,333 | 3 / 3 |
| 2026-07-27 | $-0.50 | $51,305,333 | 3 / 3 |
| 2026-07-28 | $-0.50 | $51,305,333 | 3 / 3 |
| 2026-07-29 | $-0.60 | $51,305,330 | 2 / 3 |
| 2026-07-30 | $-0.50 | $51,305,333 | 2 / 2 |
| 2026-07-31 | $-0.60 | $51,305,330 | 2 / 3 |
| 2026-08-01 | $-0.50 | $51,305,333 | 2 / 2 |
| 2026-08-02 | $-0.60 | $51,305,330 | 2 / 3 |
| 2026-08-03 | $-0.50 | $51,305,333 | 2 / 2 |
| 2026-08-04 | $-0.60 | $51,305,330 | 2 / 3 |
| 2026-08-05 | $-0.46 | $51,305,330 | 2 / 3 |
| 2026-08-06 | $-0.46 | $51,305,330 | 2 / 3 |
| 2026-08-07 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-08 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-09 | $-0.46 | $51,305,330 | 2 / 3 |
| 2026-08-10 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-12 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-13 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-14 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-15 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-16 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-17 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-18 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-19 | $-0.41 | $51,305,333 | 2 / 2 |
| 2026-08-20 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-21 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-22 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-23 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-24 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-25 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-26 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-27 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-28 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-29 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-30 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-08-31 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-01 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-02 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-03 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-04 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-05 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-06 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-07 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-08 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-09 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-10 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-11 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-12 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-13 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-14 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-15 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-16 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-17 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-18 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-19 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-20 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-21 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-22 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-23 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-24 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-25 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-26 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-27 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-28 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-29 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-09-30 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-01 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-02 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-03 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-04 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-05 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-06 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-07 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-08 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-09 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-10 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-11 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-12 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-13 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-14 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-15 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-16 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-17 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-18 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-19 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-20 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-21 | $-0.43 | $50,600,000 | 2 / 2 |
| 2026-10-22 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-23 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-24 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-25 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-26 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-27 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-28 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-29 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-30 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-10-31 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-11-01 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-11-02 | $-0.43 | $50,605,333 | 2 / 2 |
| 2026-11-03 | $-0.37 | $59,938,667 | 2 / 2 |
| 2026-11-04 | $-0.41 | $53,766,667 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.